pmcc logo sml

 

 Here are the staff publications for November 2021.

Compiled by the Health Sciences Library (RMH, RWH, PMCC & Victorian Mental Health) 1st December 2021.

 

  1. Ali AI, Wang M, von Scheidt B, Dominguez PM, Harrison AJ, Tantalo DGM, Kang J, Oliver AJ, Chan JD, Du X, Bai Y, Lee B, Johnstone RW, Darcy PK, Kershaw MH, Slaney CY. A Histone Deacetylase Inhibitor, Panobinostat, Enhances Chimeric Antigen Receptor T-cell Antitumor Effect Against Pancreatic Cancer. Clin Cancer Res 2021;27:6222-34.

  2. Alkaraki A, McArthur GA, Sheppard KE, Smith LK. Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies. Cancers (Basel) 2021;13.

  3. Brims F, Leong T, Stone E, Harden S, Marshall H, Navani N, Stirling R. Variations in lung cancer care and outcomes: How best to identify and improve standards of care? Respirology 2021;26:1103-5.

  4. Bruinsma FJ, Jordan S, Bassett JK, Severi G, MacInnis RJ, Walsh J, Aitken T, Jenkins M, Carroll R, Jefford M, Davis ID, Tucker K, Dudding-Byth T, English DR, Giles GG, Winship I, Milne RL. Analgesic use and the risk of renal cell carcinoma - Findings from the Consortium for the Investigation of Renal Malignancies (CONFIRM) study. Cancer Epidemiol 2021;75:102036.

  5. Chakraborty R, Hu H, Darido C, Vickery K, Ranganathan S. ML218 HCl Is More Efficient Than Capsaicin in Inhibiting Bacterial Antigen-Induced Cal 27 Oral Cancer Cell Proliferation. Int J Mol Sci 2021;22.

  6. Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol 2021;21:769-84.

  7. Chan RJ, Crichton M, Crawford-Williams F, Agbejule OA, Yu K, Hart NH, de Abreu Alves F, Ashbury FD, Eng L, Fitch M, Jain H, Jefford M, Klemanski D, Koczwara B, Loh K, Prasad M, Rugo H, Soto-Perez-de-Celis E, van den Hurk C, Chan A. The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. Ann Oncol 2021;32:1552-70.

  8. Copaescu AM, Phillips EJ, Trubiano JA. Antifungal hypersensitivity reactions and cross-reactivity patterns. Curr Opin Infect Dis 2021;34:559-72.

  9. Craig O, Salazar C, Gorringe KL. Options for the Treatment of Mucinous Ovarian Carcinoma. Curr Treat Options Oncol 2021;22:114.

  10. Cribb B, Kong J, Warrier S, McCormick J, Heriot A. Management of lateral pelvic lymph nodes by Australasian colorectal surgeons: An insight from the west. Asia Pac J Clin Oncol 2021;17:522-9.

  11. Davis JE, Sharpe C, Mason K, Tam CS, Koldej RM, Ritchie DS. Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence. J Transl Med 2021;19:473.

  12. De Silva DL, James PA, Mann GB, Lindeman GJ. Universal genetic testing of patients with newly diagnosed breast cancer - ready for prime time? Med J Aust 2021;215:449-53.

  13. Degeling K, Corcoran NM, Pereira-Salgado A, Hamid AA, Siva S, MJ IJ. Lifetime Health and Economic Outcomes of Active Surveillance, Radical Prostatectomy, and Radiotherapy for Favorable-Risk Localized Prostate Cancer. Value Health 2021;24:1737-45.

  14. Dickinson M, Briones J, Herrera AF, González-Barca E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola-Tompkins E, Franjkovic I, Chesne E, Brouwer-Visser J, Lechner K, Brennan B, Nüesch E, DeMario M, Rüttinger D, Kornacker M, Hutchings M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Adv 2021;5:4762-70.

  15. Downs JS, Subramaniam S, Henderson MA, Paton E, Spillane AJ, Mathy JA, Gyorki DE. A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era. J Surg Oncol 2021;124:1544-50.

  16. Edmondson RJ, O'Connell RL, Banerjee S, Mileshkin L, Sykes P, Beale P, Fisher A, Bonaventura A, Millan D, Nottley S, Benson C, Hamilton A, Sjoquist K, Alexander L, Kelly C, Carty K, Divers L, Bradshaw N, Friedlander M. Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903). Gynecol Oncol 2021;163:524-30.

  17. Emens LA, Adams S, Barrios CH, Diéras V, Iwata H, Loi S, Rugo HS, Schneeweiss A, Winer EP, Patel S, Henschel V, Swat A, Kaul M, Molinero L, Patel S, Chui SY, Schmid P. Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993. Ann Oncol 2021;32:1650.

  18. Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, Rasiah K, Pattison DA, Yaxley J, Thomas P, Hutton AC, Agrawal S, Amin A, Blazevski A, Chalasani V, Ho B, Nguyen A, Liu V, Lee J, Sheehan-Dare G, Kooner R, Coughlin G, Chan L, Cusick T, Namdarian B, Kapoor J, Alghazo O, Woo HH, Lawrentschuk N, Murphy D, Hofman MS, Stricker P. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. Eur Urol 2021;80:682-9.

  19. Fordham AM, Ekert PG, Fleuren EDG. Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas. Biochim Biophys Acta Rev Cancer 2021;1876:188613.

  20. Freeman AJ, Kearney CJ, Silke J, Oliaro J. Unleashing TNF cytotoxicity to enhance cancer immunotherapy. Trends Immunol 2021;42:1128-42.

  21. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021;32:1475-95.

  22. Godsell J, Chan S, Slade C, Bryant V, Douglass JA, Sasadeusz J, Yong MK. Cytomegalovirus in primary immunodeficiency. Curr Opin Infect Dis 2021;34:663-71.

  23. Gordon SF, Clothier HJ, Morgan H, Buttery JP, Phuong LK, Monagle P, Chunilal S, Wood EM, Tran H, Szer J, Crawford NW. Immune thrombocytopenia following immunisation with Vaxzevria ChadOx1-S (AstraZeneca) vaccine, Victoria, Australia. Vaccine 2021;39:7052-7.

  24. Hettipathirana T, Macdonald C, Xie J, Moodie K, Michael C, Phillips KA. The value of clinical breast examination in a breast cancer surveillance program for women with germline BRCA1 or BRCA2 mutations. Med J Aust 2021;215:460-4.

  25. Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, Spencer A. Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD). Leuk Lymphoma 2021;62:2981-91.

  26. Khaleel S, Regmi S, Hannah P, Watarai B, Sathianathen N, Weight C, Konety B. Impact of Preoperative Immunonutrition on Perioperative Outcomes Following Cystectomy. Reply. J Urol 2021;206:1531-2.

  27. Khaw SL, Ekert P. Cycling without brakes lets ALL escape. Blood 2021;138:1912-3.

  28. Kitchen S, Adcock DM, Dauer R, Kristoffersen AH, Lippi G, Mackie I, Marlar RA, Nair S. International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing. Int J Lab Hematol 2021;43:1272-83.

  29. Kong JC, Ngan S, Tie J, Heriot AG. Reply to: Does Total Neoadjuvant Treatment Improve Overall Survival in Rectal Cancer? No, It Does Not. Ann Surg Oncol 2021;28:795-6.

  30. Kusnadi EP, Timpone C, Topisirovic I, Larsson O, Furic L. Regulation of gene expression via translational buffering. Biochim Biophys Acta Mol Cell Res 2022;1869:119140.

  31. Lebeaux D, Coussement J, Bodilsen J, Tattevin P. Management dilemmas in Nocardia brain infection. Curr Opin Infect Dis 2021;34:611-8.

  32. Leitinger EJ, Wright RM, Nelson N, Anderson MA, Juneja S. Diagnostically challenging immunophenotypic shift in mantle cell lymphoma following ibrutinib and venetoclax therapy. Pathology 2021;53:926-9.

  33. Lindsay J, Othman J, Heldman MR, Slavin MA. Epstein-Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. Curr Opin Infect Dis 2021;34:635-45.

  34. McCoy P, Mangiola S, Macintyre G, Hutchinson R, Tran B, Pope B, Georgeson P, Hong MKH, Kurganovs N, Lunke S, Clarkson MJ, Cmero M, Kerger M, Stuchbery R, Chow K, Haviv I, Ryan A, Costello AJ, Corcoran NM, Hovens CM. MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer Prostatic Dis 2021;24:1167-80.

  35. Mead S, Lucas M, Pang JM, Fellowes A, Harraway J, Svobodova S, Amanuel B, Fox S. EGFR mutation profile in Australian patients with non-small cell lung cancer. Pathology 2021;53:933-6.

  36. Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RN. Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Mod Pathol 2021;34:2154-67.

  37. Mwangi MN, Mzembe G, Moya E, Braat S, Harding R, Robberstad B, Simpson J, Stones W, Rogerson S, Biselele K, Chinkhumba J, Larson L, Ataíde R, Phiri KS, Pasricha SR. Protocol for a multicentre, parallel-group, open-label randomised controlled trial comparing ferric carboxymaltose with the standard of care in anaemic Malawian pregnant women: the REVAMP trial. BMJ Open 2021;11:e053288.

  38. Nelson AS, Yalamarthi N, Yong MK, Blyth E. Beyond antivirals: virus-specific T-cell immunotherapy for BK virus haemorrhagic cystitis and JC virus progressive multifocal leukoencephalopathy. Curr Opin Infect Dis 2021;34:627-34.

  39. O'Brien J, Chen K, Murphy DG. Accuracy Versus Impact: The Referee Verdict on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Staging of Prostate Cancer. Eur Urol Open Sci 2021;34:83-5.

  40. Ong WL, Ball DL, Milne RL, Foroudi F, Millar JL. Evolving Practice Pattern of Palliative Radiation Therapy for Bone Metastases from Lung Cancer in Australia. Clin Oncol (R Coll Radiol) 2021;33:e530-e9.

  41. Pishas KI, Cowley KJ, Pandey A, Hoang T, Beach JA, Luu J, Vary R, Smith LK, Shembrey CE, Rashoo N, White MO, Simpson KJ, Bild A, Griffiths JI, Cheasley D, Campbell I, Bowtell DDL, Christie EL. Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer. Cancers (Basel) 2021;13.

  42. Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 2021;138:2031-41.
  43. Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, Le-Guennec S, Macé S, Dimopoulos MA. Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. Future Oncol 2021;17:4797-812.

  44. Schoenfeld AJ, Antonia SJ, Awad MM, Felip E, Gainor J, Gettinger SN, Hodi FS, Johnson ML, Leighl NB, Lovly CM, Mok T, Perol M, Reck M, Solomon B, Soria JC, Tan DSW, Peters S, Hellmann MD. Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer. Ann Oncol 2021;32:1597-607.

  45. Singh J, Facey A, O'Malley F, Ryland GL, Blombery P, Gregory GP. Cryptic molecular lesion in acute promyelocytic leukemia with negative initial FISH. Leuk Lymphoma 2021;62:3060-2.

  46. Siva S, Ost P, Zaorsky N, Staehler M. Stereotactic Radiotherapy for Oligoprogressive Disease: A New Frontier in Kidney Cancer. Eur Urol 2021;80:701-2.

  47. Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, Mazieres J, Kim DW, Mok T, Polli A, Thurm H, Calella AM, Peltz G, Shaw AT. Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer. Future Oncol 2021;17:4649-56.

  48. Steffens D, Ismail H, Denehy L, Beckenkamp PR, Solomon M, Koh C, Bartyn J, Pillinger N. ASO Visual Abstract: Preoperative Cardiopulmonary Exercise Test Associated with Postoperative Outcomes for Patients Undergoing Cancer Surgery-A Systematic Review and Meta-Analyses. Ann Surg Oncol 2021;28:502.

  49. Teh BW, Tam CS. Between a rock and a hard place: COVID-19 vaccination and patients on rituximab therapy. Leuk Lymphoma 2021;62:2820-2.

  50. Thai AA, Lim AM, Solomon BJ, Rischin D. Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13.

  51. Thursky KA, Hardefeldt LY, Rajkhowa A, Ierano C, Bishop J, Hawes L, Biezen R, Saha SK, Dowson L, Bailey KE, Scarborough R, Little SB, Gotterson F, Hur B, Khanina A, Urbancic K, Crabb HK, Richards S, Sri A, James R, Kong DCM, Marshall C, Mazza D, Peel T, Stuart RL, Manski-Nankervis JA, Friedman ND, Bennett N, Schulz T, Billman-Jacobe H, Buono E, Worth L, Bull A, Richards M, Ayton D, Gilkerson JR, Browning GF, Buising KL. Antimicrobial stewardship in Australia: the role of qualitative research in programme development. JAC Antimicrob Resist 2021;3:dlab166.

  52. Tian L, Jabbari JS, Thijssen R, Gouil Q, Amarasinghe SL, Voogd O, Kariyawasam H, Du MRM, Schuster J, Wang C, Su S, Dong X, Law CW, Lucattini A, Prawer YDJ, Collar-Fernández C, Chung JD, Naim T, Chan A, Ly CH, Lynch GS, Ryall JG, Anttila CJA, Peng H, Anderson MA, Flensburg C, Majewski I, Roberts AW, Huang DCS, Clark MB, Ritchie ME. Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. Genome Biol 2021;22:310.

  53. Toivanen R, Porter LH, Li Z, Clouston D, Risbridger GP, Taylor RA. Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. Cancer Lett 2022;524:182-92.

  54. Trappetti V, Fernandez-Palomo C, Smyth L, Klein M, Haberthür D, Butler D, Barnes M, Shintani N, de Veer M, Laissue JA, Vozenin MC, Djonov V. Synchrotron Microbeam Radiation Therapy for the Treatment of Lung Carcinoma: A Preclinical Study. Int J Radiat Oncol Biol Phys 2021;111:1276-88.

  55. Tudini E, Davidson AL, Dressel U, Andrews L, Antill Y, Crook A, Field M, Gattas M, Harris R, Kirk J, Pachter N, Salmon L, Susman R, Townshend S, Trainer AH, Tucker KM, Mitchell G, James PA, Ward RL, Mar Fan H, Poplawski NK, Spurdle AB. Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility. J Med Genet 2021;58:853-8.

  56. Van Bockstal MR, François A, Altinay S, Arnould L, Balkenhol M, Broeckx G, Burguès O, Colpaert C, Dedeurwaerdere F, Dessauvagie B, Duwel V, Floris G, Fox S, Gerosa C, Hastir D, Jaffer S, Kurpershoek E, Lacroix-Triki M, Laka A, Lambein K, MacGrogan GM, Marchiò C, Martin Martinez MD, Nofech-Mozes S, Peeters D, Ravarino A, Reisenbichler E, Resetkova E, Sanati S, Schelfhout AM, Schelfhout V, Shaaban A, Sinke R, Stanciu-Pop CM, van Deurzen CHM, Van de Vijver KK, Van Rompuy AS, Vincent-Salomon A, Wen HY, Wong S, Bouzin C, Galant C. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Mod Pathol 2021;34:2130-40.

  57. Wang D, Cabalag CS, Clemons NJ, DuBois RN. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology 2021;161:1813-29.

  58. Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, Badoux XC, Kuss BJ, Jackson S, Moreno C, Jacobs R, Pagel JM, Flinn I, Pak Y, Zhou C, Szafer-Glusman E, Ninomoto J, Dean JP, James DF, Ghia P, Tam CS. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. J Clin Oncol 2021;39:3853-65.

  59. Wong SW, Vivash L, Mudududdla R, Nguyen N, Hermans SJ, Shackleford DM, Field J, Xue L, Aprico A, Hancock NC, Haskali M, Stashko MA, Frye SV, Wang X, Binder MD, Ackermann U, Parker MW, Kilpatrick TJ, Baell JB. Development of [(18)F]MIPS15692, a radiotracer with in vitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. Eur J Med Chem 2021;226:113822.

  60. Yanes T, Meiser B, Kaur R, Young MA, Mitchell PB, Scheepers-Joynt M, McInerny S, Taylor S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, Betz-Stablein B, James PA. Breast cancer polygenic risk scores: a 12-month prospective study of patient reported outcomes and risk management behavior. Genet Med 2021;23:2316-23.

  61. Yip RKH, Rimes JS, Capaldo BD, Vaillant F, Mouchemore KA, Pal B, Chen Y, Surgenor E, Murphy AJ, Anderson RL, Smyth GK, Lindeman GJ, Hawkins ED, Visvader JE. Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis. Nat Commun 2021;12:6920.

  62. Youssef A, Haskali MB, Gorringe KL. The Protein Landscape of Mucinous Ovarian Cancer: Towards a Theranostic. Cancers (Basel) 2021;13.